Skip to main content
. 2020 Feb 24;25(5):369–374. doi: 10.1634/theoncologist.2019-0671

Figure 1.

Figure 1

CT imaging evaluations of a 57‐year‐old male treated by an anti‐programmed death‐ligand 1 immunotherapy combined with another immune checkpoint modulator for metastatic urothelial carcinoma. First imaging evaluation performed at week 6 showed progressive disease by RECIST 1.1 with a 42.5% target lesions progression and appearance of new lesions. Abbreviation: CT, computed tomography.